OCUL biotech catalysts & pipeline

OCULAR THERAPEUTIX INC · Data as of 2026-10-25

Upcoming catalysts

AXPAXLI — Interim data

Q4 2026

The NDA submission will be based on SOL-1 efficacy and safety data, an interim SOL-R safety analysis of patients who have reached Week 52 to be conducted in the fourth quarter of 2026, and confirmatory evidence.

Source filing

AXPAXLI — NDA/BLA submission

Q4 2026

New Drug Application (NDA) submission for AXPAXLI in wet AMD planned for Q4 2026, with FDA alignment confirmed in May 2026 Type C meeting minutes.

Source filing

AXPAXLI — Topline data

Q1 2028

Topline data for the SOL-R trial are expected to be available in the first quarter of 2028.

Source filing

Explore the free biotech catalyst calendar